Dimensional Fund Advisors LP Boosts Stock Position in IQVIA Holdings Inc. $IQV

Dimensional Fund Advisors LP increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,422,064 shares of the medical research company’s stock after acquiring an additional 12,508 shares during the quarter. Dimensional Fund Advisors LP owned about 0.84% of IQVIA worth $269,990,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alliancebernstein L.P. lifted its holdings in IQVIA by 0.6% during the second quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock valued at $560,379,000 after purchasing an additional 19,573 shares in the last quarter. Artisan Partners Limited Partnership increased its stake in shares of IQVIA by 4.9% in the third quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after purchasing an additional 161,085 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of IQVIA by 22.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares during the period. Nordea Investment Management AB raised its position in shares of IQVIA by 12.3% during the 3rd quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after purchasing an additional 253,759 shares during the period. Finally, Cantillon Capital Management LLC lifted its stake in shares of IQVIA by 27.3% during the 3rd quarter. Cantillon Capital Management LLC now owns 1,926,934 shares of the medical research company’s stock valued at $366,002,000 after buying an additional 413,256 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IQV. BMO Capital Markets set a $250.00 price target on IQVIA in a research note on Friday, February 6th. Royal Bank Of Canada initiated coverage on IQVIA in a research report on Tuesday. They issued an “outperform” rating and a $221.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. TD Cowen lifted their target price on IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Finally, Truist Financial lowered their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $231.13.

IQVIA Trading Down 2.2%

IQV stock opened at $174.56 on Friday. The firm has a fifty day moving average price of $207.22 and a 200 day moving average price of $207.37. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The firm has a market cap of $29.62 billion, a PE ratio of 22.21, a price-to-earnings-growth ratio of 1.72 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business had revenue of $4.36 billion during the quarter, compared to analyst estimates of $4.24 billion. During the same quarter last year, the business earned $3.12 earnings per share. IQVIA’s quarterly revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.